Related Experiment Videos
Immunobiology of D-penicillamine
The Journal of Rheumatology. Supplement
|January 1, 1981
Summary
D-penicillamine offers insights into autoimmune diseases by affecting immunoregulation and immunogenicity, particularly in myasthenia gravis. Its complex actions may involve HLA-linked genes influencing anti-striated muscle antibody production.
Area of Science:
- Immunology
- Autoimmune Diseases
- Pharmacology
Background:
- D-penicillamine's multifaceted effects complicate understanding its role in autoimmune diseases.
- Autoimmune diseases involve complex interactions between genetic factors and immune responses.
Purpose of the Study:
- To elucidate the mechanism of D-penicillamine in autoimmune conditions, focusing on autoimmunization and pathogenesis.
- To investigate the influence of D-penicillamine on anti-acetylcholine receptor antibodies and myasthenia gravis.
- To explore the role of human leukocyte antigen (HLA) in the immune response to striated muscle antibodies.
Main Methods:
- Analysis of D-penicillamine's diverse pharmacological actions.
- Assessment of D-penicillamine's impact on immunoregulation and immunogenicity.
- Correlation of anti-striated muscle antibody prevalence with patient HLA antigen types.
Main Results:
- D-penicillamine's primary effect in myasthenia gravis may involve immunoregulation or immunogenicity.
- Anti-striated muscle antibodies are frequently observed and are associated with specific patient HLA antigens.
- Evidence suggests a potential role for HLA-linked immune response genes in autoimmune pathogenesis.
Conclusions:
- D-penicillamine provides a valuable model for studying autoimmunization and autoimmune disease pathogenesis.
- The drug's effects on immune regulation and antibody production are critical areas for further research.
- HLA genetics significantly influence immune responses in autoimmune conditions like myasthenia gravis.